Delpharm

Executive Summary

Delpharm is a leading French Contract Development and Manufacturing Organization (CDMO) founded in 1993, specializing in the development and production of pharmaceutical drugs across solid, sterile, semi-solid, and liquid dosage forms. With a global network of facilities, the company provides high-quality, safe, and effective therapeutic solutions to pharmaceutical partners. As a private company, Delpharm operates with a focus on operational excellence and strategic expansion to meet growing demand for outsourced drug manufacturing. The CDMO segment benefits from increasing drug development pipelines and the trend toward outsourcing, positioning Delpharm for steady growth. However, limited public disclosure constrains visibility into financial performance and specific growth drivers. The company's ability to secure long-term contracts and expand capacity will be key to maintaining its competitive edge in the evolving pharmaceutical landscape.

Upcoming Catalysts (preview)

• Q4 2026New Manufacturing Capacity Expansion70% success
• Q2 2026Major Contract Win with Top Pharma Partner50% success
• Q3 2026FDA or EMA Approval for a Client’s Drug Manufactured by Delpharm60% success